News Summary: Baxter drug Gammagard fails to slow Alzheimer’s progression in big study

DISAPPOINTMENT: A product that Baxter International was testing failed to slow mental decline or preserve physical function in a major study of 390 patients with mild to moderate Alzheimer’s disease.

THE DETAILS: People who received 18 months of infusions with Gammagard fared no better than others given placebo. Gammagard is made from natural antibodies culled from donated blood. Researchers thought it might help remove amyloid, the sticky plaque that clogs Alzheimer patients’ brains.

URGENT NEED: About 35 million people worldwide have dementia, and Alzheimer’s is the most common type. Current treatments temporarily ease symptoms — there is no known cure.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.